Aribio's oral Alzheimer's treatment candidate AR1001 (generic name mirodenafil) has achieved its primary evaluation goal in a global Phase 3 trial. In a group that did not take existing dementia medications, the drug slowed disease progression by 31%. This indicates the potential for an oral new drug in a market primarily focused on injectable treatments. However, the overall patient group did not statistically prove effectiveness.
On November 16, during the Alzheimer's Clinical Trials Conference (CTAD 2026) held in Boston, Aribio presented the 52-week results of its global Phase 3 trial (POLARIS-AD). The presentation was led by Sharon Sha, the clinical trial's principal investigator from Stanford University. The trial involved 1,535 early Alzheimer's patients across approximately 230 institutions in 13 countries. Patients received either 30 mg of AR1001 or a placebo once daily for 52 weeks.
The trial was designed in consultation with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to evaluate two groups: the overall patient group and the monotherapy group. Achieving significance in either group would fulfill the primary goal. The monotherapy group consisted of 604 patients who were not taking existing symptomatic treatments such as donepezil or memantine. Aribio had previously confirmed cognitive function and biomarker improvements in this patient group during a Phase 2 trial, designating it as a key analysis target from the Phase 3 design stage.
The primary evaluation metric, the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), showed that in the monotherapy group, the AR1001 group experienced a deterioration of 0.44 points less than the placebo group. This translates to a 31% delay in disease progression, approximately 3.5 months. In contrast, the difference in the overall patient group was only 0.11 points, failing to achieve statistical significance.
The secondary evaluation metrics also indicated greater effects in the monotherapy group. In the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), there was a 1.16-point difference compared to the placebo, but it did not reach statistical significance. The Mini-Mental State Examination (MMSE) showed a significant difference of 0.7 points.
Evidence also emerged that the drug acts in the brain. AR1001 inhibits the PDE5 enzyme, preventing the breakdown of the signaling molecule (cGMP) involved in neuroprotection. At the 52-week mark, cGMP levels in cerebrospinal fluid were significantly higher in both groups compared to the placebo group. The tau protein marker associated with Alzheimer's progression (p-tau217) significantly decreased in the monotherapy group, while there was no difference in amyloid markers.
Safety was generally favorable. Adverse reactions were reported in 69.0% of the treatment group and 66.4% of the placebo group, with most being mild or moderate. The incidence of serious adverse reactions was similar, at 10.0% for the treatment group and 9.8% for the placebo group. However, diarrhea (7.7%) and dizziness (6.1%) occurred more frequently in the treatment group. The discontinuation rate due to adverse reactions was higher in the treatment group at 5.2% compared to 1.7% in the placebo group.
Professor Sha stated, "The pre-specified results of the CDR-SB in the monotherapy group and the safety profile are encouraging. POLARIS-AD represents another advancement in addressing the unmet medical needs for early Alzheimer's patients who require more diverse treatment options."
A key advantage of AR1001 is that it is an oral medication. Currently, the approved Alzheimer's treatments in the U.S., Leqembi and Kisqali, are both injectables, requiring regular MRI scans to monitor for side effects like brain edema and hemorrhage. AR1001's once-daily dosing could enhance convenience for patients.
Aribio is also solidifying its commercialization plans. In May, the company signed a global exclusive option agreement for AR1001 worth $4.74 billion with Fuxing Pharmaceutical in China, targeting major markets including the U.S., Europe, and Japan, excluding South Korea, the Middle East, and Latin America. They will receive an upfront option fee of $60 million for clinical development. The company aims to apply for FDA approval next year and plans to commercialize by 2028. Aribio CEO Jung Jae-jun stated, "We aim to quickly enter the FDA approval application process based on these global clinical trial results."
Long-term effect verification will continue. About 95% of patients who completed the 52-week trial have entered an extension study to continue taking AR1001. James Locke, Aribio's Chief Clinical Officer, noted, "Ongoing commitment from participants and caregivers is essential for the 52-week treatment period and the current extension study. We will also announce the results of AR1001 in the ongoing extension study in the future."
These results hold significance for the domestic bio industry as well. A domestic company has successfully conducted a large-scale global Phase 3 trial and presented the results at an international conference. This lays the groundwork for challenging global approval for an oral Alzheimer's disease progression-slowing treatment. This could serve as a milestone for K-bio, which has faced criticism for lacking experience in global approval clinical trials.
However, market reactions have been lukewarm. As of 11:17 AM on the Korea Exchange, Aribio's stock was trading at 4,070 won, down 29.95% from the previous trading day, hitting the lower limit. The inability to prove effectiveness in the overall patient group is believed to have dampened investor sentiment.
The key question is how global regulatory agencies, including the FDA, will interpret the Phase 3 data. While the monotherapy group met the primary evaluation criteria, the overall patient group did not achieve statistical significance. The results of the ongoing long-term extension study (OLE) following the 52-week trial may also impact the approval review.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.